Class I Recalls Break Record; FDA Begins Product-Specific Inquiries
This article was originally published in The Silver Sheet
Executive SummaryRECALLS OF MEDICAL DEVICES REACHED A RECORD LEVEL IN 2004, with 612 actions reported. A dramatic rise in Class I recalls has prompted FDA’s device center to look more closely at worrisome trends in certain product areas, including in vitro diagnostics. A new agency requirement for press releases on all Class I recalls should please consumers and members of Congress demanding greater openness from FDA, but a leading IVD industry spokeswoman questions the policy’s value to public health. Recent enforcement actions are a reminder that Class I recalls almost invariably lead to FDA scrutiny of a firm’s quality system
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.